new_adrs_0322_1244|MIST|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_adrs_0322_1244|MIST|1|Milestone Pharmaceuticals Inc Total Current Assets (Quarterly) (USD)|Milestone Pharmaceuticals Inc Cash and Short Term Investments (Quarterly) (USD)|Milestone Pharmaceuticals Inc Inventories (Quarterly) (USD)|Milestone Pharmaceuticals Inc Net PP&E (Quarterly) (USD)|Milestone Pharmaceuticals Inc Goodwill and Intangibles (Quarterly) (USD)|Milestone Pharmaceuticals Inc Total Liabilities (Quarterly) (USD)|Milestone Pharmaceuticals Inc Total Current Liabilities (Quarterly) (USD)|Milestone Pharmaceuticals Inc Total Long Term Liabilities (Quarterly) (USD)|Milestone Pharmaceuticals Inc Total Deposits (Quarterly) (USD)|Milestone Pharmaceuticals Inc Book Value (Quarterly) (USD)|Milestone Pharmaceuticals Inc Retained Earnings (Quarterly) (USD)|Milestone Pharmaceuticals Inc Treasury Stock (Quarterly) (USD)|Milestone Pharmaceuticals Inc EV to Revenues|Milestone Pharmaceuticals Inc EV to Earnings|Milestone Pharmaceuticals Inc EV to Free Cash Flow|Milestone Pharmaceuticals Inc EV to Assets (Quarterly)|Milestone Pharmaceuticals Inc PS Ratio|Milestone Pharmaceuticals Inc PE Ratio|Milestone Pharmaceuticals Inc Price to Book Value|Milestone Pharmaceuticals Inc PEG Ratio|Milestone Pharmaceuticals Inc Debt to Equity Ratio|Milestone Pharmaceuticals Inc Dividend Yield|Milestone Pharmaceuticals Inc Shareholder Yield (TTM)|Milestone Pharmaceuticals Inc Percent of Shares Outstanding Short|Milestone Pharmaceuticals Inc Total Receivables (Quarterly) (USD)|Milestone Pharmaceuticals Inc Total Payables (Quarterly) (USD)|Milestone Pharmaceuticals Inc Total Capital Stock (Quarterly) (USD)|Milestone Pharmaceuticals Inc Return on Invested Capital|Milestone Pharmaceuticals Inc Quality Ratio Score|Milestone Pharmaceuticals Inc Momentum Score|Milestone Pharmaceuticals Inc Beta (1Y)|Milestone Pharmaceuticals Inc Sustainable Growth Rate (TTM)|Milestone Pharmaceuticals Inc Institutional Investor Ownership Percentage|Milestone Pharmaceuticals Inc Average Diluted Shares Outstanding (Quarterly)|Milestone Pharmaceuticals Inc Total Employees (Annual)|Milestone Pharmaceuticals Inc EPS Diluted (Quarterly) (USD)|Milestone Pharmaceuticals Inc Shares Outstanding|Milestone Pharmaceuticals Inc Repurchase of Capital Stock (Quarterly) (USD)|Milestone Pharmaceuticals Inc Ordinary Shares Number (Quarterly)|Milestone Pharmaceuticals Inc Payout Ratio|Milestone Pharmaceuticals Inc Quick Ratio (Quarterly)|Milestone Pharmaceuticals Inc Normalized Diluted EPS (Quarterly) (USD)|Milestone Pharmaceuticals Inc Stock Buybacks (Quarterly) (USD)|Milestone Pharmaceuticals Inc Effective Tax Rate (TTM)|Milestone Pharmaceuticals Inc Return on Equity|Milestone Pharmaceuticals Inc Net Income (TTM) (USD)|Milestone Pharmaceuticals Inc Revenue (TTM) (USD)|Milestone Pharmaceuticals Inc Dividend Per Share (Quarterly) (USD)|Milestone Pharmaceuticals Inc Revenue (Quarterly) (USD)|Milestone Pharmaceuticals Inc Gross Profit (Quarterly) (USD)|Milestone Pharmaceuticals Inc SG&A Expense (Quarterly) (USD)|Milestone Pharmaceuticals Inc Pre-Tax Income (Quarterly) (USD)|Milestone Pharmaceuticals Inc Net Income (Quarterly) (USD)|Milestone Pharmaceuticals Inc Net Interest Income (Quarterly) (USD)|Milestone Pharmaceuticals Inc Price (USD)|Milestone Pharmaceuticals Inc Total Return Price (USD)|Milestone Pharmaceuticals Inc Enterprise Value (USD)|Milestone Pharmaceuticals Inc 30-Day Average Daily Volume|Milestone Pharmaceuticals Inc 1 Year Price Returns (Daily)||
new_adrs_0322_1244|MIST|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_adrs_0322_1244|MIST|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
new_adrs_0322_1244|MIST|5|91.2727272727|91.2727272727||91.2727272727||91.2727272727|91.2727272727|91.2727272727||91.2727272727|91.2727272727||||6.91390728477|92|||6.93006993007|||1.4479889043||15.223880597|91.2727272727|91.2727272727|91.2727272727|||32|30.380952381|||91.3571428571|91.375|91.3571428571|31.724137931||91.2727272727|||91.3571428571|91.5|91.25||91.2727272727|||||91.3571428571|91.3571428571|91.3571428571|91.3571428571|6.91390728477|6.91390728477|6.91390728477|6.91034482759|1.44444444444||
new_adrs_0322_1244|MIST|6|11|11||11||11|11|11||11|11||||151|1|||143|||721||67|11|11|11|||19|21|||14|8|14|29||11|||14|10|4||11|||||14|14|14|14|151|151|151|145|468||
new_adrs_0322_1244|MIST|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_adrs_0322_1244|MIST|201803||||||||||||||||||||||||||||||||||23.6476||-0.1768||||||-0.1768|||||||||1.164|-4.165|-4.181|0.09|||||||
new_adrs_0322_1244|MIST|201806||||||||||||||||||||||||||||||||||23.6476||-0.1518||||||-0.1518|||||||||1.125|-3.587|-3.589|0.089|||||||
new_adrs_0322_1244|MIST|201809||||||||||||||||||||||||||||||||||23.6476||-0.241||||||-0.241|||||||||1.874|-5.7|-5.7|0.085|||||||
new_adrs_0322_1244|MIST|201812|88.051|85.976||0.03||143.291|4.533|138.758||-55.21|-58.27||||||||||||||0.677|3.357|2.039|||||||23.6476|20|-0.4109|||23.1476|||-0.4109||-0.3202||-23.187|||||2.81|-9.661|-9.717|0.446|||||||
new_adrs_0322_1244|MIST|201903|77.279|71.268||0.309||143.014|4.152|138.862||-65.426|-68.722||||-14.3796|||||||||0.0529|0.529|2.409|2.09|||||||23.1476|23|-0.4515|23.1476||23.1476|||-0.4515||-0.2723||-29.458|||||3.165|-10.43|-10.452|0.5|21.16|21.16|446.5722||||
new_adrs_0322_1244|MIST|201906|151.551|145.824||0.286||6.524|6.463|0.061||145.313|-82.38||||-19.1156||||3.0289|||||0.0848|0.695|3.952|226.211|||||||13.1906|23|-1.04|24.4907||24.4907|||-1.04|-86.092|-0.1876||-39.527|||||3.807|-13.662|-13.658|0.672|27.15|27.15|593.6545|42867.6333||17.53|22.6
new_adrs_0322_1244|MIST|201909|140.971|136.501||0.921||9.06|8.836|0.224||132.832|-95.211||||-8.094||||3.1365|||||0.062|0.953|4.338|226.211|||||||24.4907|30|-0.52|24.4907||24.4907|||-0.52|0.731|-0.0021||-46.658|||||4.18|-12.904|-12.831|0.821|18.9|18.9|317.0502|10314.7333||20.5|16.87
new_adrs_0322_1244|MIST|201912|122.499|119.818||0.929||8.511|8.327|0.184||114.917|-113.499||||-5.7074||||3.4141|||||0.0621|0.836|6.153|226.245|||||||24.5057|30|-0.7463|24.5057||24.5057|||-0.7463|-0.002|0.1013||-55.229|||||4.743|-18.289|-18.288|0.603|15.4|15.4|240.6943|18300.3||22.05|19
new_adrs_0322_1244|MIST|202003|104.324|101.816||0.832||5.524|5.366|0.158||99.632|-129.842||||1.0391||||0.4536|||||1.4127|0.943|2.72|226.378||||4.3833|||24.5488|30|-0.67|24.5595||24.5595|||-0.67||||-61.12|||||4.886|-16.343|-16.343|0.415|1.84|1.84|-56.6265|904253.6667|-84.9524|2.42|3.4
new_adrs_0322_1244|MIST|202006|92.406|85.426||0.733||5.123|4.991|0.132||88.016|-142.821||||-0.1329||||1.0605|||||5.3574|0.848|2.791|226.676|||1|4.3486|||24.628|28|-0.53|24.693||24.693|||-0.53||||-60.441|||||4.483|-12.979|-12.979|0.126|3.78|3.78|7.9135|1307787.1333|-86.0773|8.01|7.97
new_adrs_0322_1244|MIST|202009|107.419|102.91||1.378||6.599|5.881|0.718||102.198|-154.8||||-1.6986||||2.1196|||||1.8769|1.005|4.938|226.758|||1|4.991|||29.7741|28|-0.4|24.727||24.727|||-0.4||||-59.589|||||3.857|-11.996|-11.979|0.089|7.55|7.55|101.1353|281808.4333|-60.7507|5.68|6.68
new_adrs_0322_1244|MIST|202012|148.686|142.31||1.288||6.855|6.159|0.696||143.119|-163.466||||-1.6594||||1.9581|||||1.0866|0.948|5.598|251.682|||1|4.533|||38.3912|28|-0.13|29.828||29.828|||-0.13|-24.917|||-49.967|||||2.996|-8.666|-8.666|0.096|6.71|6.71|97.2017|105729.5333|-58.1512|8|7.54
new_adrs_0322_1244|MIST|202103|137.244|129.859||1.199||6.451|5.816|0.635||131.992|-175.98||||-0.6012||||1.2074|||||1.128|1.093|3.928|251.716|||1|3.4984|||41.2562||-0.3|29.846||29.846|||-0.3||||-46.138|||||3.999|-12.514|-12.514|0.08|5.79|5.79|30.4983|92591|214.6739|5.84|5.61
new_adrs_0322_1244|MIST|202106|144.386|135.794||1.109||5.901|5.328|0.573||139.594|-175.21||||-0.932|0.1949|||1.3024|||||0.7734|1.145|4.62|251.716|||7|2.6628|||44.5301||0.02|29.846||29.846||25.7018|0.02||||-32.389|||15||4.861|0.77|0.77|0.058|5.76|5.76|42.054|58532.0333|45.5026|5.45|6.07
new_adrs_0322_1244|MIST|202109|132.758|126.426||1.018||6.359|5.847|0.512||127.417|-189.435||||-1.1812|0.3033|||1.2059|||||0.6117|0.364|5.216|251.766|||2|1.2126|||42.1829||-0.34|29.8698||29.8698|||-0.34||||-34.635|||||4.54|-14.225|-14.225|0.048|5.64|5.64|32.5374|34227.3|-21.9945|5.655|5.47
new_adrs_0322_1244|MIST|202112|||||||||||||||-2.4902||||1.5708|||||0.2181||||||3|0.1306||||||||||||||||||||||||6.7|6.7|73.7198|49724.5667|-2.2388|6.93|5.83
new_adrs_0322_1244|MIST|202203|||||||||||||||-1.2389||||1.2801||||||||||||||||||||||||||||||||||||5.46|5.46|36.6779|84367.4333|-22.3329||